The present invention relates to nanostructures that, after
in vivo administration, are excreted in the
urine via the kidneys without being phagocytosed by macrophages and / or metabolized, and their use as pharmaceutical compositions. A
nanostructure for
in vivo administration according to the present invention comprises (i) a spherical core formed by crosslinking two or three
dextran molecules with an average molecular weight of 10,000 Da or less using a crosslinker and (ii) a discontinuous shell with
divalent or trivalent iron ions coordinationally bonded to crosslinker-derived hydrophilic groups on the surface of the spherical core; and (iii) a
mass ratio of
dextran to iron
ranging from 100 : 2 to 100 : 10, with a crosslinker substitution ratio adjusted to 10% to 50% of the total number of functional groups on the
dextran, while 20% to 50% of the crosslinker does not participate in crosslinking at the terminal end, resulting in the
nanostructure having the charge
ranging from -20 mV to 0 mV; (iv) wherein only 20% to 80% of the crosslinker-derived hydrophilic groups externally exposed on the surface of the spherical core bind iron ions, while the remainder do not bind iron ions and are exposed to an aqueous environment.